| Name | Title | Contact Details |
|---|
SyntheZyme develops bio-based products and technologies with a unique and competitive cost/performance. We work closely together with our industrial partners for the manufacture and marketing of our bio-based commodity and specialty products for the global market. We seek to complement our core competencies with those of our strategic, industrial partners. The success of our business is based on our capabilities to structure and operate entrepreneurial partnerships. SyntheZyme’s scientists and engineers have a deep knowledge in chemistry, synthetic biology, fermentation engineering and materials science with process know-how
The Phyto-Microbiome Company Biological Optimizers for Soil, Seed and Plant Vigor Inocucor is an agri-tech company that develops powerful natural biological products for agriculture targeting the phyto-microbiome—the seeds, plants, root systems and the soil surrounding them. Inocucor`s first-generation product, Garden Solution®, soon to be re-branded as Synergro, employs live microbes to actively improve the health of the entire phyto-microbiome. Its second product, Synergro Free and future generations of Inocucor products are powerful biological formulations for bio-stimulation, bio-fertility and bio-control targeting mainstream production agriculture.
Anox Kaldnes Inc is a Providence, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Practical Applications is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At BioNTech we understand that every cancer patient`s tumor is unique and therefore each patient`s treatment should be individualized. To pioneer the next generation of patient-specific immunotherapies, we have combined ground-breaking research with cutting-edge technologies to develop therapeutics for cancer and beyond. Our broad and synergistic suite of platforms, which include mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators have been optimized for distinct modes of action, high precision targeting, high potency and efficacy. We are also developing in parallel our own state-of-the-art manufacturing processes to complement our drug development platforms. We were founded in 2008 in Mainz, Germany and have been driven to become the leading global biotechnology company for individualized cancer medicine. We have over 20 product candidates in development, 8 candidates in 9 ongoing clinical trials, treated over 250 patients across 17 tumor types and supported by more than 1100 employees. As we prove the value of our approach in the clinic, we continue to build a network of world-class corporate and scientific collaborators, manufacturing and team required to bring individualized treatments to patients worldwide.